Access cutting-edge multiple myeloma treatment through this clinical trial at a research site in San Francisco. Study-provided care at no cost to qualified participants.
Access multiple myeloma specialists in San Francisco at no cost
This study follows strict safety protocols and ethical guidelines
All study-related multiple myeloma treatment provided free
The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, including an anti-CD38 monoclonal antibody and an immunomodulatory drug. The primary objective of this study is to compare the efficacy of anitocabtagene autoleucel versus SOCT in participants with RRMM.
Sponsor: Kite, A Gilead Company
Check if you qualify for this multiple myeloma clinical trial in San Francisco, CA
If you're searching for multiple myeloma treatment options in San Francisco, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our San Francisco research site is actively enrolling participants for this clinical trial. You'll receive care from experienced multiple myeloma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.